AKR1C1 and ovarian carcinoma: We show that an inhibition of this pathway either by NFE2L2 silencing or direct AKR1C1/2 inhibition by MPA resensitizes ovarian cancer cells to CTX and results in reduced viability, proliferation, and an increased apoptosis rate.